© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
AML
Novel IDH1 Inhibitor Demonstrates Safety and Preliminary Efficacy in R/R AML
October 26, 2020
The IDH1 inhibitor olutasidenib showed a favorable safety profile in patients with relapsed/refractory acute myeloid leukemia treated in a phase 1/2 clinical trial, according to topline results.
New ASH Guidelines Highlight a Call to Action for Treatment of Older AML Patients
October 20, 2020
New guidelines from he American Society of Hematology for treating newly diagnosed acute myeloid leukemia in older patients recommend intensive antileukemic therapies over more conservative approaches.
FDA Approves Venetoclax Plus LDAC For Older Patients With Newly Diagnosed AML
October 16, 2020
The FDA granted approval to venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine, a regimen known as LDAC, as treatment of adults patients with aged 75 years or older with newly-diagnosed acute myeloid leukemia or who have comorbidities precluding intensive induction chemotherapy.
CC-486 Constitutes Standard of Care for Subset of Patients with AML
September 05, 2020
In an interview with Targeted Oncology Guillermo Garcia-Manero, MD, discussed the key findings from the QUAZAR AML-001 study and the importance of the FDA approval of CC-486 in post-remission acute myeloid leukemia.
FDA Approves CC-486 as Maintenance Therapy in Acute Myeloid Leukemia
September 01, 2020
The FDA granted approval to the oral hypomethylating agent, CC-486 (azacitidine tablets, Onureg), as a maintenance treatment for adult patients with acute myeloid leukemia who achieved a first complete remission or with incomplete blood count recovery after intensive induction chemotherapy and who are unable to complete intensive curative therapy.
Enasidenib Misses Primary End Point, Appears Safe in Phase 3 Study of R/R Acute Myeloid Leukemia
August 25, 2020
Overall survival was not improvement with the combination of enasidenib and best supportive care compared with conventional care regimens when administered to patients relapsed/refractory IDH2-positive acute myeloid leukemia.
FDA Grants Fast Track Designation to BST-236 for Older Adults With Acute Myeloid Leukemia
August 04, 2020
The FDA has granted a Fast Track designation to BST-236 for the treatment of patients with acute myeloid leukemia who are 75 years or older or have comorbidities that preclude the use of intensive induction chemotherapy.
Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients
July 31, 2020
Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.
Sorafenib Maintenance May Prevent Recurrence After Transplant in FLT3-ITD+ AML
July 21, 2020
The risk of relapse or death was reduced by 61% with sorafenib maintenance compared with placebo following allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD–positive acute myeloid leukemia.
Expansion of AML Treatment Landscape Underscores Importance of Molecular Testing
July 17, 2020
In an interview with Targeted Oncology, Yousef Zakharia, MD, discussed the current treatment landscape for acute myeloid leukemia and how he goes about sequencing the available agents when he treats patients in clinic.